|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-10-22
|
|
pubmed:abstractText |
Inadequate response to cisplatin-based chemotherapy is associated with poor prognosis in patients with advanced malignant testicular germ cell tumours (TGCTs), especially of the nonseminomatous type. Novel chemotherapeutic agents have failed so far to significantly improve the outcome of such patients. The majority of these tumours express low levels of p53, and TP53 mutations are rarely observed. Murine double minute 2 (Mdm2) inhibitors enhance apoptosis in tumours harbouring wild-type p53.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/CDKN1A protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Cisplatin,
http://linkedlifedata.com/resource/pubmed/chemical/Cyclin-Dependent Kinase Inhibitor...,
http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/MDM2 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Piperazines,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins c-mdm2,
http://linkedlifedata.com/resource/pubmed/chemical/TP53 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Tumor Suppressor Protein p53,
http://linkedlifedata.com/resource/pubmed/chemical/nutlin 3
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
1873-7560
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright © 2009 European Association of Urology. Published by Elsevier B.V. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
57
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
679-87
|
|
pubmed:meshHeading |
pubmed-meshheading:19560254-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:19560254-Apoptosis,
pubmed-meshheading:19560254-Carcinoma, Embryonal,
pubmed-meshheading:19560254-Cell Line, Tumor,
pubmed-meshheading:19560254-Cell Proliferation,
pubmed-meshheading:19560254-Cell Survival,
pubmed-meshheading:19560254-Cisplatin,
pubmed-meshheading:19560254-Cyclin-Dependent Kinase Inhibitor p21,
pubmed-meshheading:19560254-Dose-Response Relationship, Drug,
pubmed-meshheading:19560254-Drug Resistance, Neoplasm,
pubmed-meshheading:19560254-Enzyme Inhibitors,
pubmed-meshheading:19560254-Humans,
pubmed-meshheading:19560254-Imidazoles,
pubmed-meshheading:19560254-Inhibitory Concentration 50,
pubmed-meshheading:19560254-Male,
pubmed-meshheading:19560254-Mutation,
pubmed-meshheading:19560254-Piperazines,
pubmed-meshheading:19560254-Proto-Oncogene Proteins c-mdm2,
pubmed-meshheading:19560254-Testicular Neoplasms,
pubmed-meshheading:19560254-Tumor Suppressor Protein p53
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Therapeutic potential of Mdm2 inhibition in malignant germ cell tumours.
|
|
pubmed:affiliation |
Sarcoma Centre, West German Cancer Centre, University Hospital Essen, Essen, Germany. sebastian.bauer@uni-due.de
|
|
pubmed:publicationType |
Journal Article
|
